Aduro Biotech (ADRO) to Acquire BioNovion in EUR 29M Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Grand Canyon Education places CFO on leave amid stock trade probe
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
Aduro Biotech Enters Into Definitive Agreement to Acquire Premier Antibody Portfolio and Engineering Capabilities Through Purchase of BioNovion
September 24, 2015 4:00 PM EDTAduro's innovative technology portfolio broadens with BioNovion's well-established antibody discovery and optimization capabilities  Aduro's preclinical pipeline expands to include immune checkpoint inhibitors and other monoclonal antibody candidates with unique specificity  Terms include initial payment of 14.5 million Euro in cash and 14.5 million Euro in Aduro stock, plus future contingent payments  Aduro will host a conference call today at 1:30 pm Pacific to discuss the transaction
BERKELEY, Calif. and OSS, The Netherlands, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq: ADRO) and BioNovion Holding B.V. announced today that they... More
